59 results
8-K
EX-1.1
PROK
ProKidney Corp - Ordinary Shares
13 Jun 24
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
9:06am
material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries
424B5
PROK
ProKidney Corp - Ordinary Shares
13 Jun 24
Prospectus supplement for primary offering
7:00am
citizens or long-term residents of the United States;
persons who own, have owned, or will own (directly or through attribution) 10% or more (by vote … the amount realized and the U.S. Holder’s adjusted tax basis in the Class A ordinary shares. Any such capital gain or loss generally will be long-term capital
424B5
PROK
ProKidney Corp - Ordinary Shares
10 Jun 24
Prospectus supplement for primary offering
5:13pm
or instrumentalities thereof;
regulated investment companies and real estate investment trusts;
expatriates and former citizens or long-term residents … . Holder’s adjusted tax basis in the Class A ordinary shares. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S
8-K
EX-99.2
PROK
ProKidney Corp - Ordinary Shares
10 Jun 24
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
8:00am
) Diabetes Type II – Prevent/Delay ESRD in Stage 3b/4 CKD 2 016/PROACT 2 Ongoing (20-44 ml/min/1.73m , n=600) Long term follow-up study for patients previously
8-K
EX-10.1
ookd soqh6
25 Mar 24
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
4:07pm
8-K
EX-99.1
u0met4nx
26 Jan 24
Regulation FD Disclosure
12:00am
8-K
EX-1.1
1tm7xhz
19 Jan 24
Entry into a Material Definitive Agreement
4:19pm
424B5
ufs9 btxow2met7py1
19 Jan 24
Prospectus supplement for primary offering
4:16pm
8-K/A
EX-10.1
a430s
5 Dec 23
Departure of Directors or Certain Officers
4:06pm
8-K
EX-99.1
a9oae
13 Nov 23
Departure of Directors or Certain Officers
5:28pm
8-K
EX-99.1
mesy0j2 e19
11 Sep 23
Regulation FD Disclosure
8:01am
424B3
x081mdyvln o0x
22 Aug 23
Prospectus supplement
7:13pm
POS AM
7vn02bdrikm ro
18 Aug 23
Prospectus update (post-effective amendment)
4:07pm
8-K
EX-99.1
x3y hp6okd6c0lkk
10 Aug 23
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
4:33pm
DEF 14A
prlraho
26 May 23
Definitive proxy
8:00am